Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $290.54M |
| Gross Profit (TTM) | $235.92M |
| EBITDA | $133.01M |
| Operating Margin | 13.50% |
| Return on Equity | 22.00% |
| Return on Assets | 3.99% |
| Revenue/Share (TTM) | $14.75 |
| Book Value | $48.57 |
| Price-to-Book | 6.16 |
| Price-to-Sales (TTM) | 20.28 |
| EV/Revenue | 19.68 |
| EV/EBITDA | 20.64 |
| Quarterly Earnings Growth (YoY) | 825.00% |
| Quarterly Revenue Growth (YoY) | 33.70% |
| Shares Outstanding | $19.94M |
| Float | $19.49M |
| % Insiders | 2.32% |
| % Institutions | 115.95% |
Volatility is currently expanding
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital.
Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is highlighted as a reliable midcap pharma with a high-growth business model.
Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m.
Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026.
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LGND and any ticker you trade — then tracks every position and per-strategy win rate.
